1
|
Gay LM, Elvin JA, Vergilio JA, Killian JK, Ramkissoon S, Severson E, Daniel S, Hammerich A, Sokol E, Frampton G, Chung J, Trabucco S, Ali S, Reddy P, Schrock AB, Miller VA, Ross JS. Abstract P3-06-18: Comprehensive genomic profiling of carcinosarcomas of the breast. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-06-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Carcinosarcomas of the breast (BCSC) are exceptionally rare and the underlying genomic drivers are still being elucidated. Comprehensive genomic profiling (CGP) determines the tumor mutation burden (TMB) and identifies all four classes of genomic alterations (GA) that have potential to direct personalized treatment strategies.
Methods:
CGP by hybridization capture of exons from up to 315 cancer-related genes and select introns of 28 genes commonly rearranged in cancer was applied to ≥ 50ng of DNA extracted from 9 consecutive BCSC and sequenced to high, uniform median coverage (>500X). Tumor mutational burden (TMB) was determined on 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined by principal components analysis of optimized loci.
Results:
The 9 BCSC patients had a median age of 57 yrs (range 49-78 yrs). CGP was performed on the primary BCSC in 4 cases and on metastasis biopsies in 5 cases (4 lung and 1 lymph node). The mean GA/tumor was 6.6 and clinically relevant GA (CRGA)/tumor was 1.3. The most frequent non-CRGA were in TP53 (89%), MYC (56%) and LYN (40%). The most frequent CRGA were in PIK3CA (33%), and NF1, BRCA1, PTEN, RICTOR, FGFR1, AKT2 and STK11 (all at 11%). The median TMB for all BCSC was 2.4 mut/Mb with 1 (11%) tumor with a TMB > 20 mut/Mb and 8 BCSC (88%) with TMB < 5 mut/Mb. Five of 5 BCSC (100%) that were available for MSI status testing were microsatellite stable.
Conclusions:
On CGP, BCSC feature a high frequency of GA, but only a modest frequency of CRGA and high TMB. However, when the CRGA and TMB positive cases are combined (77.8% overall in this series), the opportunity for personalized targeted and immunotherapies are significant. Thus, further investigation of precision therapies for BCSC in the clinical trial setting appear warranted.
Citation Format: Gay LM, Elvin JA, Vergilio J-A, Killian JK, Ramkissoon S, Severson E, Daniel S, Hammerich A, Sokol E, Frampton G, Chung J, Trabucco S, Ali S, Reddy P, Schrock AB, Miller VA, Ross JS. Comprehensive genomic profiling of carcinosarcomas of the breast [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-06-18.
Collapse
Affiliation(s)
- LM Gay
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - JA Elvin
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - J-A Vergilio
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - JK Killian
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - S Ramkissoon
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - E Severson
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - S Daniel
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - A Hammerich
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - E Sokol
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - G Frampton
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - J Chung
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - S Trabucco
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - S Ali
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - P Reddy
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - AB Schrock
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - VA Miller
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| | - JS Ross
- Foundation Medicine, Inc., Cambridge, MA; Upstate Medical University, Syracuse, NY
| |
Collapse
|
2
|
Bello S, Rinaldi A, Trabucco S, Serafino L, Bonali C, Lapadula G. Erasmus syndrome in a marble worker. Reumatismo 2015; 67:116-22. [PMID: 26876191 DOI: 10.4081/reumatismo.2015.826] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2015] [Revised: 10/13/2015] [Accepted: 10/13/2015] [Indexed: 11/23/2022] Open
Abstract
Erasmus syndrome is defined as the association of silica exposure and subsequent development of systemic sclerosis. The limited number of cases reported in the literature mainly involves miners and only sporadically other professionals. We describe a case of Erasmus syndrome in a marble worker. A 68 year old man came to our observation complaining pelvic and scapular girdle pain, evening fever, intense weakness and emaciation for about 1 month. He also reported to have had Raynaud's phenomenon in his hands for the last 13 years. Also, his occupational history revealed a chronic exposure to silica dust. The patient presented pain in his shoulders and hips, moderate skin thickening and sclerosis in his hands and fingers extending proximally to his wrists. The diagnosis of systemic sclerosis was determined according to his clinical and medical history, the positivity of anti-Scl 70 antibodies, the nailfold capillaroscopy suggestive of an active scleroderma pattern and the detection of a mild restrictive pulmonary syndrome. The evaluation of the organbased complications excluded a gastroenterological and cardiovascular involvement, while the chest computed tomography (CT) detected multiple small nodules with a mantle distribution and enlarged lymph nodes with no signs of interstitial lung disease and fibrosis. Additional tests (positron emission tomography-CT, flexible bronchoscopy and broncho-alveolar lavage) excluded infectious diseases and cancer. However, given the pulmonary involvement, we performed a histological examination of the parenchyma and lymph nodes, which revealed a picture of pneumoconiosis. In the end, the occupational history and the findings from the diagnostic procedures led to the diagnosis of pulmonary silicosis. The precise definition of the pulmonary involvement was essential to the therapeutic approach to this patient.
Collapse
Affiliation(s)
- S Bello
- Rheumatology Unit, Policlinico Hospital, University of Bari, Bari.
| | | | | | | | | | | |
Collapse
|
3
|
Grossi V, Lucarelli G, Matrone A, Forte G, Germani A, Rutigliano M, Stella A, Bagnulo R, Loconte D, Galleggiante V, Sanguedolce F, Cagiano S, Bufo P, Trabucco S, Ditonno P, Battaglia M, Resta N, Simone C. 401 Loss of LKB1/STK11 expression is an early event in prostate cancer development and predicts therapeutic response to p38α inhibitor. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/s1569-9056(15)60395-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Abstract
e16120 Background: Neuroendocrine differentiation (NED) in prostate carcinoma (PC) is frequently detected by immunohistochemistry as single cells in conventional adenocarcinoma. NED of PC correlates with poor prognosis and tumor progression during androgen-deprivation therapy. The aim of our study was to correlate the expression of somatostatin receptor (SSTR) 1, 2, 3, 4, 5 subtypes in primary PC with NED pattern and Overall Survival (OS). Methods. PC tissues were reviewed from 100 pts who had undergone biopsy or radical prostatectomy for previously untreated advanced or metastatic PC from 2002 to 2007. 24 samples expressed hystologically chromogranin A (CgA), a marker of NED expression. Patient characteristics included: median age 68 years (range 45–83), median baseline PSA: 70 ng/ml (range 0.3–200), median ECOG Performance Status: 1 (range 0–2), Gleason score ≥ 7, medium serum level of CgA was 56.2 nmol/L (range 0.5–120). Results: The expression of SSTR subtypes (1, 2, 3, 4, 5) were investigated and our data identified four histological features. SSTR1 was expressed in 4/24 samples, SSTR 5 was detected in 2/24 samples, both SSTR1 and SSTR5 were found in 6/24 samples. OS at last follow up on July 2008 was 60%. SSTR 1–5 were undetectable in 12/24 pts with more aggressive clinical course and the OS was < 10%. The PSA and CgA levels were not correlated with clinical outcome. SSTR subtypes 2, 3 an 4 were not expressed in all 24 samples. Conclusions: SSTRs expression significantly correlated with OS. The absence of SSTR 1 and 5 in more aggressive disease could represent a growth advantage in NED prostate cancer. SSTRs and somatostatin analogs are potential targets for prostate cancer treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Gernone
- Unit of Medical Oncology, Bari, Italy; Uroloigic Unit II, Bari, Italy; Anatomopathology Unit, Bari, Italy
| | - V. Pagliarulo
- Unit of Medical Oncology, Bari, Italy; Uroloigic Unit II, Bari, Italy; Anatomopathology Unit, Bari, Italy
| | - S. Trabucco
- Unit of Medical Oncology, Bari, Italy; Uroloigic Unit II, Bari, Italy; Anatomopathology Unit, Bari, Italy
| |
Collapse
|
7
|
Di Lorenzo L, Trabucco S, Massola A, Corfiati M, Bello A, Soleo L. [A case of occupational lung disease (welder lung) in a mechanical worker]. G Ital Med Lav Ergon 2007; 29:840-843. [PMID: 18409991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
A case of welder's lung is reported in a male hard smoker who had worked as welder-carpenter for almost 30 years. In order to establish an etiologic diagnosis, given the informed consent from the worker, open lung biopsy was performed that allowed to obtain sufficiently large specimens of affected lung to make histological, immunohistochemical and mineralogical examination. In such a way the pathologic features were accurately defined and a multidisciplinary approach was applied to differential diagnosis. The worker is recommended to undergo a strict health surveillance because of the reported association of welder's lung with lung cancer, especially in smokers.
Collapse
Affiliation(s)
- L Di Lorenzo
- Dipartimento di Medicina Interna e Medicina Pubblica, Sezione di Medicina del Lavoro "E. C. Vigliani", Università di Bari, Policlinico di Bari, 70124 Bari, Italy.
| | | | | | | | | | | |
Collapse
|
8
|
Gernone A, Trabucco S, Troccoli G, Pagliarulo V, Pagliarulo A. Prognostic role of chromogranin A expression for docetaxel response in hormone-refractory metastatic prostate cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15528 Background: The neuroendocrine (NE) cells in prostate cancer are indistinguishable from non-NE cancer cells morphologically and are usually detected by immunohistochemical study for NE markers. We analyzed the expression of Chromogranin A (Chr A) in malignant prostate tissue as prognostic factor for docetaxel response in metastatic HRPC. Methods: From January 2003 to December 2006, 40 patients with metastatic HRPC received a median of 12 cycles (range 2–18) of Docetaxel 75 mg/mq every 21 days and 5 mg of prednisone twice daily as initial therapy. Tissue blocks from primary prostate cancer tissues were obtained and immunostaining for Chr A was performed. The median age was 70 years (range 46–82); median baseline PSA: 310 ng/ml (range 0.15–700); median ECOG Performance Status: 1 (range 0- 2). PSA level was measured every 4 weeks and the treatment was considered effective if a rate of PSA-decline > 50% from baseline was found. TTP was the preliminary end point. Results: Response to Docetaxel was assessed at every 3 cycles of treatment. The Chr A expression was found in 19/40 patients with Gleason = 7, PSA < 20, bone and soft tissue metastasis; 10 of them showed PR (decrease in PSA < 50%), 4 SD and TTP was 9.2 months. Moreover they received second line chemotherapy without significant efficacy. 5/19 patients with Chr A expression showed PD, the PSA level was not correlated with clinical outcome, TTP was 5 months and were chemoresistant to different line treatment. Besides, Chr A was not detected in 21/40 patients with Gleason = 7, PSA > 20 and bone metastasis; 10 of them showed CR (PSA normalized) and 11 PR, TTP was 20 months. Conclusions: NE differentiation do not constituite a different histopathological category of prostate cancer but the NE phenotype can be correlated with poorly differentiated adenocarcinoma. NE differentiation can be considered a factor that influences prognosis and treatment in advanced prostate cancer; cases with Chr A expression did not benefit from Docetaxel and had poor prognosis. These preliminary data indicate that initial therapeutic approach should be different according to Chr A expression. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Gernone
- Unit of Medical Oncology, Bari, Italy; Anatomopathology Unit II, Bari, Italy; Urologic Unit, Bari, Italy
| | - S. Trabucco
- Unit of Medical Oncology, Bari, Italy; Anatomopathology Unit II, Bari, Italy; Urologic Unit, Bari, Italy
| | - G. Troccoli
- Unit of Medical Oncology, Bari, Italy; Anatomopathology Unit II, Bari, Italy; Urologic Unit, Bari, Italy
| | - V. Pagliarulo
- Unit of Medical Oncology, Bari, Italy; Anatomopathology Unit II, Bari, Italy; Urologic Unit, Bari, Italy
| | - A. Pagliarulo
- Unit of Medical Oncology, Bari, Italy; Anatomopathology Unit II, Bari, Italy; Urologic Unit, Bari, Italy
| |
Collapse
|
9
|
Lucarelli G, Mancini V, Annunziata G, Trabucco S, Palazzo S, Ditonno P, Battaglia M, Selvaggi F. Adult Type Testicular Granulosa Cell Tumor: Case Report and Review of the Literature. Urologia 2006. [DOI: 10.1177/039156030607300307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Granulosa cell tumors represent a special group of the so-called sex cord-stromal tumors of the gonads, and are divided into 2 histological types: adult and juvenile. Adult type testicular granulosa cell tumor is a rare neoplasia: 22 cases of this testicular tumor only have been described in literature so far. They are often discovered accidentally and exhibit no endocrine-related symptoms. We report a case of adult type granulosa cell tumor in a 45-year-old man likely affected by a 15-year-old painless tumor with increased right testicular size; he underwent radical orchiectomy. This case and a review of the literature indicate that this kind of tumor is a rare, slow-growing neoplasm. Since distant metastases may occur late in the clinical course, long term follow-up of these patients is recommended.
Collapse
Affiliation(s)
- G. Lucarelli
- Dipartimento dell'Emergenza e dei Trapianti d'Organo, Sezione di Urologia e Trapianto di Rene
| | - V. Mancini
- Dipartimento dell'Emergenza e dei Trapianti d'Organo, Sezione di Urologia e Trapianto di Rene
| | - G. Annunziata
- Dipartimento dell'Emergenza e dei Trapianti d'Organo, Sezione di Urologia e Trapianto di Rene
| | - S. Trabucco
- Dipartimento dell'Emergenza e dei Trapianti d'Organo, Sezione di Urologia e Trapianto di Rene
- Dipartimento di Anatomia Patologica e di Genetica, Sezione di Anatomia Patologica II, Università degli Studi di Bari, Bari
| | - S. Palazzo
- Dipartimento dell'Emergenza e dei Trapianti d'Organo, Sezione di Urologia e Trapianto di Rene
| | - P. Ditonno
- Dipartimento dell'Emergenza e dei Trapianti d'Organo, Sezione di Urologia e Trapianto di Rene
| | - M. Battaglia
- Dipartimento dell'Emergenza e dei Trapianti d'Organo, Sezione di Urologia e Trapianto di Rene
| | - F.P. Selvaggi
- Dipartimento dell'Emergenza e dei Trapianti d'Organo, Sezione di Urologia e Trapianto di Rene
| |
Collapse
|